APW
CRSP icon

Allied Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Allied Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59 Buy
+1
New +$53 ﹤0.01% 886

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allied Private Wealth's CRSP Position: Q2 2026 in Review

Allied Private Wealth opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 1 share worth $59. The stake represents ﹤0.01% of the portfolio and ranks #886 among its holdings.

522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Allied Private Wealth held 1 share of CRISPR Therapeutics worth $59 as of Q2 2026.
  • CRISPR Therapeutics was a new Allied Private Wealth position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Allied Private Wealth's portfolio in Q2 2026, its #886 holding.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Allied Private Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.